Minerva Neurosciences (NERV) Consolidated Net Income (2013 - 2026)

Minerva Neurosciences (NERV) posted Consolidated Net Income of -$32.3 million for Q1 2026, down 466.37% on a QoQ basis from -$5.7 million in Q4 2025, and down 762.9% year-over-year from $4.9 million in Q1 2025.

Minerva Neurosciences (NERV) Consolidated Net Income (2013 - 2026) Analysis & Trends

Minerva Neurosciences' Consolidated Net Income history runs 14 years deep, the most recent figure standing at -$32.3 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 762.9% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 143.59% YoY) and the FY2025 annual result came in at -$113.8 million, up 2.4% from the prior year.
  • Consolidated Net Income was -$32.3 million for Q1 2026 at Minerva Neurosciences, down from -$5.7 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at -$2.7 million in Q3 2025 and bottomed at -$103.7 million in Q4 2023.
  • A 5-year average of -$18.0 million and a median of -$5.9 million in 2024 frame the typical range for Consolidated Net Income.
  • Annual changes were most pronounced in 2024 — Consolidated Net Income soared 95.83% — and 2026, when it slumped 762.9%.
  • Minerva Neurosciences' Consolidated Net Income stood at -$94.9 million in 2022, then decreased by 9.27% to -$103.7 million in 2023, then surged by 95.83% to -$4.3 million in 2024, then slumped by 31.8% to -$5.7 million in 2025, then sank by 466.37% to -$32.3 million in 2026.
  • Business Quant data shows NERV's Consolidated Net Income at -$32.3 million in Q1 2026, -$5.7 million in Q4 2025, and -$2.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Oculis Holding AG 66,140.12 Bn 66,139.83 Bn - -37.09 Mn
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn - -14.46 Mn
4 BeOne Medicines 472.04 Bn 467.25 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 122.28 Bn 115.03 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.66 Bn 62.66 Bn - -26.94 Mn
8 Argenx Se 56.16 Bn 50.98 Bn 1.41 Bn 362.00 Mn
9 Alnylam Pharmaceuticals 37.56 Bn 34.55 Bn 959.66 Mn 205.99 Mn
10 Minerva Neurosciences 183.94 Mn 183.94 Mn - -32.31 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -32.31 Mn
Dec 31, 2025 -5.71 Mn
Sep 30, 2025 -2.74 Mn
Jun 30, 2025 -3.24 Mn
Mar 31, 2025 -3.74 Mn
Dec 31, 2024 -4.33 Mn
Sep 30, 2024 -4.05 Mn
Jun 30, 2024 -5.93 Mn
Mar 31, 2024 -6.32 Mn
Dec 31, 2023 -103.68 Mn
Sep 30, 2023 -6.77 Mn
Jun 30, 2023 -6.18 Mn
Mar 31, 2023 -4.98 Mn
Dec 31, 2022 -94.88 Mn
Sep 30, 2022 -5.66 Mn
Jun 30, 2022 -6.89 Mn
Mar 31, 2022 -8.04 Mn
Dec 31, 2021 -21.37 Mn
Sep 30, 2021 -7.71 Mn
Jun 30, 2021 -8.98 Mn